CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Progen Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Progen Co Ltd
6-7F, 172, Magokjungang-ro, Gangseo-gu
Phone: +82 260982800p:+82 260982800 SEOUL, 07789  South Korea Ticker: 296160296160
Business Summary
Progen Co Ltd is a Korea-based company principally engaged in the researching and developing new drugs. The Company produces metabolic disease treatment drugs, immune disease treatment drugs, immune anticancer drugs, and others. The Company was established in 1998.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

General Information
Number of Employees: 44 (As of 12/31/2023)
Outstanding Shares: 11,656,228 (As of 8/30/2024)
Shareholders: 835
Stock Exchange: KON
Fax Number: +82 260982849


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024